Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Liver Dis. 2011 Aug;15(3):515-36. doi: 10.1016/j.cld.2011.05.002.

An overview of emerging therapies for the treatment of chronic hepatitis C.

Author information

  • 1Liver Center, St Luke's Episcopal Hospital, Baylor College of Medicine, Houston, TX 77030, USA.

Abstract

Chronic hepatitis C (CHC) is a leading cause of chronic hepatitis, cirrhosis, liver failure, and hepatocellular carcinoma (HCC) worldwide. Currently, pegylated interferon (Peg-IFN) and ribavirin therapy achieve curative responses in 40% to 80% of patients, depending on genotype. Recognition of new therapeutic targets for HCV therapy has led to development of novel therapies. The purpose of this review is to summarize the status of novel therapeutics for CHC that promise to increase the safety and efficacy of therapy.

PMID:
21867934
DOI:
10.1016/j.cld.2011.05.002
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center